Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025
Co-Diagnostics (NASDAQ:CODX) announced its participation at WHX Kuala Lumpur, Southeast Asia's leading healthcare exhibition, from July 16-18, 2025 at MITEC. The event, expecting over 10,000 visitors from 54 countries, will serve as a platform for CODX to showcase its PCR diagnostics portfolio.
The company will promote its Co-Primers® technology and introduce its upcoming Co-Dx™ PCR platform, including the Co-Dx PCR MTB test and 8-plex Co-Dx HPV test, both scheduled for clinical evaluations later this year. The company's participation is partially supported by a grant from World Trade Center Utah.
Co-Diagnostics (NASDAQ:CODX) ha annunciato la sua partecipazione a WHX Kuala Lumpur, la principale fiera sanitaria del Sud-est asiatico, che si terrà dal 16 al 18 luglio 2025 presso il MITEC. L'evento, che prevede oltre 10.000 visitatori provenienti da 54 paesi, rappresenterà una piattaforma per CODX per presentare il suo portafoglio di diagnostica PCR.
L'azienda promuoverà la sua tecnologia Co-Primers® e presenterà la sua prossima piattaforma Co-Dx™ PCR, inclusi il test Co-Dx PCR MTB e il test Co-Dx HPV 8-plex, entrambi programmati per valutazioni cliniche entro la fine dell'anno. La partecipazione dell'azienda è parzialmente sostenuta da una sovvenzione del World Trade Center Utah.
Co-Diagnostics (NASDAQ:CODX) anunció su participación en WHX Kuala Lumpur, la principal feria de salud del Sudeste Asiático, que se llevará a cabo del 16 al 18 de julio de 2025 en MITEC. El evento, que espera más de 10,000 visitantes de 54 países, será una plataforma para que CODX muestre su portafolio de diagnóstico PCR.
La compañía promoverá su tecnología Co-Primers® e introducirá su próxima plataforma Co-Dx™ PCR, incluyendo la prueba Co-Dx PCR MTB y la prueba Co-Dx HPV 8-plex, ambas programadas para evaluaciones clínicas a finales de este año. La participación de la empresa cuenta con el apoyo parcial de una subvención del World Trade Center Utah.
Co-Diagnostics (NASDAQ:CODX)는 2025년 7월 16일부터 18일까지 MITEC에서 열리는 동남아시아 최대 의료 전시회인 WHX 쿠알라룸푸르에 참가한다고 발표했습니다. 이번 행사에는 54개국에서 10,000명 이상의 방문객이 예상되며, CODX는 자사의 PCR 진단 포트폴리오를 선보일 기회로 활용할 예정입니다.
회사는 Co-Primers® 기술을 홍보하고, 올해 말 임상 평가가 예정된 Co-Dx PCR MTB 검사와 8-plex Co-Dx HPV 검사 등 차세대 Co-Dx™ PCR 플랫폼을 소개할 계획입니다. 이번 참여는 World Trade Center Utah의 보조금 지원을 일부 받았습니다.
Co-Diagnostics (NASDAQ:CODX) a annoncé sa participation à WHX Kuala Lumpur, le principal salon de la santé en Asie du Sud-Est, qui se tiendra du 16 au 18 juillet 2025 au MITEC. L'événement, qui attend plus de 10 000 visiteurs venus de 54 pays, sera une plateforme pour CODX afin de présenter son portefeuille de diagnostics PCR.
L'entreprise mettra en avant sa technologie Co-Primers® et présentera sa prochaine plateforme Co-Dx™ PCR, incluant le test Co-Dx PCR MTB et le test Co-Dx HPV 8-plex, tous deux prévus pour des évaluations cliniques plus tard cette année. La participation de l'entreprise est partiellement financée par une subvention du World Trade Center Utah.
Co-Diagnostics (NASDAQ:CODX) gab seine Teilnahme an der WHX Kuala Lumpur bekannt, der führenden Gesundheitsmesse Südostasiens, die vom 16. bis 18. Juli 2025 im MITEC stattfindet. Die Veranstaltung, die über 10.000 Besucher aus 54 Ländern erwartet, bietet CODX eine Plattform, um sein PCR-Diagnostik-Portfolio zu präsentieren.
Das Unternehmen wird seine Co-Primers®-Technologie bewerben und die kommende Co-Dx™ PCR-Plattform vorstellen, darunter den Co-Dx PCR MTB-Test und den 8-plex Co-Dx HPV-Test, die beide noch in diesem Jahr klinisch evaluiert werden sollen. Die Teilnahme des Unternehmens wird teilweise durch einen Zuschuss des World Trade Center Utah unterstützt.
- None.
- None.
WHX Kuala Lumpur, formerly Asia Health/Medlab Asia, is the leading healthcare exhibition in
The Company expects to use the opportunity to increase interest in its suite of PCR in vitro diagnostics for infectious diseases, to promote its Co-Primers® technology and applications, and to introduce its upcoming Co-Dx™ PCR platform*, including the Co-Dx PCR MTB test and the 8-plex Co-Dx HPV test, both of which remain on track to begin clinical evaluations later this year.
Attendees interested in learning more about the Company are invited to visit Booth L18. Details about the event can be found here.
Company travel and conference attendance is made possible due in part to a grant from World Trade Center Utah, a member of the World Trade Centers Association founded in 2006 with the goal of helping
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-whx-kuala-lumpur-on-july-16-18-2025-302505363.html
SOURCE Co-Diagnostics
FAQ
When and where is Co-Diagnostics (CODX) presenting at WHX Kuala Lumpur 2025?
What products will Co-Diagnostics (CODX) showcase at WHX Kuala Lumpur 2025?
How many visitors are expected at WHX Kuala Lumpur 2025?
When will Co-Diagnostics begin clinical evaluations for its new tests?
